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Summary
Chemotherapeutic agents simultaneously induce transcription factors p53 and NFB. p53 induction can activate an apo-
ptotic program, and resistance to chemotherapy correlates with the loss of a functional p53 pathway. By contrast, NFB
prevents apoptosis in response to chemotherapeutic agents. We have analyzed the p53 response in IKK1/2/ MEFs, which
lack detectable NFB activity. Compared to WT fibroblasts, IKK1/2/ fibroblasts showed increased cell death and p53
induction in response to the chemotherapeutic agent, doxorubicin. Reconstitution of IKK2, but not IKK1, increased Mdm2
levels and decreased doxorubicin-induced p53 stabilization and cell death. IKK2-mediated effects required its kinase
function and were abrogated by coexpression of the dominant negative IBM, implying a role for NFB in blocking
chemotherapy-induced p53 and cell death.
Introduction for regulating this degradation (Haupt et al., 1997; Honda and
Yasuda, 1999; Kubbutat et al., 1997). Mutant forms of p53 accu-
mulate in cells because they fail to transcriptionally activateCytotoxicity of chemotherapeutic agents has been attributed to
apoptosis, a form of programmed cell death (Chao et al., 2000). Mdm2. The loss of a wild-type p53 response creates a permis-
sive environment for acquisition of genomic instability (Yin etHowever, acquisition of resistance to the cytotoxic effects of
chemotherapy has emerged as a significant impediment to ef- al., 1992), which can lead to secondary mutations that can
engender resistance to the cytotoxicity of chemotherapeuticfective cancer therapy. The tumor suppressor protein p53, a
sequence-specific transcription factor, is a key modulator of agents.
NFB is a family of ubiquitously expressed dimeric sequenceapoptosis in response to chemotherapeutic agents (Levine,
1997; Lowe et al., 1993a). As p53 plays a central role in sensing specific transcription factors. Initially recognized for controlling
gene expression and function in the immune system, the impor-and maintaining genetic integrity, its activation and function
have been extensively investigated (Levine, 1997; Oren, 1999). tance of NFB family members in modulating cellular growth,
apoptosis, and development is now well documented. In mostVarious cellular signals, including activation of oncogenes (Deb-
bas and White, 1993; Serrano et al., 1997), DNA damage (Huang unstimulated cells, the NFB dimers are bound in the cytoplasm
by inhibitory IB molecules (Verma et al., 1995). Since transcrip-et al., 1996), and hypoxia (Graeber et al., 1994), lead to activation
of p53, resulting in either apoptosis or cell cycle arrest. The tional activation by NFB requires its nuclear translocation, sig-
nal-induced degradation of IB molecules is considered a keychoice between these outcomes likely depends, among other
factors, on the genetic variability (Polyak et al., 1996) and the rate-limiting step in NFB activation (Karin and Ben-Neriah,
2000). Phosphorylation of IB molecules at specific serine resi-extent of p53 activation (Chen et al., 1996). Regulation of p53
mainly occurs posttranscriptionally, often via posttranslational dues immediately precedes their ubiquitin-mediated degrada-
tion (Chen et al., 1995). Two serine threonine IB kinases (IKK),modifications that increase its half-life and nuclear concentra-
tion (Prives, 1998). In normal cells, p53 protein is rapidly turned IKK1 and IKK2, which are 52% identical, were identified to be
responsible for phosphorylating and targeting IB molecules forover due to ubiquitin-mediated proteolytic degradation (Bottger
et al., 1997). Interaction of p53 with Mdm2, a protein that is degradation. Both IKK1 (also called IKK) and IKK2 (also called
IKK) normally reside in a large 700 kDa complex in the cyto-transcriptionally activated by p53 (Wu et al., 1993), is crucial
S I G N I F I C A N C E
Our results demonstrate that IKK2, a central regulator of the antiapoptotic pathway controlled by the oncogenic transcription factor
NFB, can collaterally downregulate the proapoptotic pathway controlled by the tumor suppressor p53. Our data also distinguishes
between the functions of the highly homologous kinases, IKK1 and IKK2, in response to chemotherapy. Given that these kinases
have distinct in vivo roles, our results suggest that rather than using generic IKK inhibitors, specific inhibitors of IKK2 could be used
as adjuvants to existing chemotherapy regimens. Collectively, our results provide a mechanism of acquisition of resistance to
chemotherapeutic agents that activate both NFB and p53 and also suggest a role for the deregulated NFB activity observed in
several leukemias, lymphomas, and breast cancers.
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plasm. In addition to these two kinases, the IKK complex also WT embryos. Compared to WT MEFs, IKK1/2/ MEFs were
consists of other regulatory proteins (Yamaoka et al., 1998). A more sensitive to DoxR-induced cell death (Figure 1A). Further
genetic dissection of the different roles played by these kinases characterization of DoxR mediated cell death in these MEFs
has been provided by the generation of IKK1 (Li et al., 1999a; indicated that cell death resulted from apoptosis (data not
Takeda et al., 1999) and IKK2 knockout mice (Li et al., 1999b, shown). Gel shift analysis to detect the activation of NFB in
1999c; Tanaka et al., 1999). Mice lacking both IKK1 and IKK2 response to varying doses of DoxR revealed NFB DNA binding
die embryonically at day 9.5 (Li et al., 2000). Unlike murine activity in WT but not in IKK1/2/ MEFs (data not shown).
embryo fibroblasts (MEFs) derived from IKK1/ and Since p53 plays an important role in DoxR-mediated cell
IKK2/animals, MEFs derived from IKK1/2/ double knockout death (Lowe et al., 1993a), we analyzed the induction of p53 in
embryos are severely defective in NFB activation, reiterating WT and IKK1/2/ MEFs. A titration of DoxR revealed that p53
that these are the two essential kinases involved in NFB activa- induction in the IKK1/2/ MEFs occurred at a lower dose of
tion (Li et al., 2000). DoxR (Figure 1B, compare lanes 3–6 and 9–12). Similar results
Both NFB and p53 are activated in response to many stim- were obtained using two independent sets of WT and IKK1/
uli, including DNA damage (Devary et al., 1993; Wang et al., 2/ MEFs. Densitometric analysis revealed between 2–5 fold
1996) and TNF (Donato and Perez, 1998). It is conceivable higher p53 in IKK1/2/ cells. The levels of p65, IKK1, and IKK2
that these transcription factors, which have been documented remained unchanged upon DoxR titration. RT-PCR analysis re-
to have largely opposite effects in response to stress, modulate vealed no significant differences in p53 expression between WT
each other’s activities. Indeed, competition for limiting pools of and IKK1/2/ cells (data not shown). These results suggest
transcriptional coactivators p300 and CBP has been reported that lack of IKK activity sensitizes cells to p53 stabilization in
to mediate a bidirectional repression between NFB and p53 response to DoxR. More importantly, induction of p53 is not
(Webster and Perkins, 1999). In addition, transactivation of the dependent on NFB activity.
p53 promoter by NFB in response to TNF (Wu and Lozano, To understand the increased sensitivity of IKK1/2/ MEFs
1994) and anticancer drugs (Hellin et al., 1998; Sun et al., 1995) to DoxR, we evaluated the integrity of the DNA damage-induced
has been observed. p53 response in these cells. Phosphorylation of N-terminal ser-
Although mutational inactivation of p53 is observed in well ine 18 in murine p53 (corresponding to serine 15 in human p53)
over 50% of all human cancers (Hollstein et al., 1994), a signifi- contributes to p53 activation by DNA damage (Chao et al.,
cant fraction of cancers express wild-type p53, which may be 2000). Figure 1C demonstrates that DoxR treatment induces
inactivated by other mechanisms, such as increased Mdm2 comparable levels of S18 phosphorylation in both WT and
expression resulting from gene amplification (Oliner et al., 1992), IKK1/2/ MEFs (lanes 2 and 4). Total p53 induction was mea-
increased Raf (Ries et al., 2000), or Akt signaling (Zhou et al., sured by PA421 antibody (top panel, Figure 1C). We evaluated
2001). One potential additional mechanism might involve the the transactivation potential of the activated p53 by measuring
activation of antiapoptotic genes that compete with proapo- protein levels of the cyclin-dependent kinase inhibitor p21, a
ptotic pathways activated by p53. NFB is a well-documented key target gene of p53 (el-Deiry et al., 1993). Figure 1D demon-
antiapoptotic factor, which is turned on simultaneously along strates that DoxR treatment induced expression of p21 protein
with p53 in response to chemotherapeutic agents (Pahl, 1999; in both WT and IKK1/2/ MEFs. It is worth noting that there
Wang et al., 1996). Inhibition of NFB has been documented are higher endogenous levels of p21 (Figure 1D, compare lane
to lead to increased efficacy of anticancer drugs (Cusack et 1 and 3) in the IKK1/2/ MEFs, which is consistent with the
al., 1999, 2001). In nude mice, tumors derived from HT1080 enhanced p53 stabilization in these MEFs (Figure 1B). The sub-
fibrosarcoma cells (Wang et al., 1999) or from the colorectal
cellular localization of DoxR-induced p53 and p21 in both WT
tumor cell line LoVo (Cusack et al., 2000) are more sensitive to
and IKK1/2/ MEFs is nuclear (data not shown). Retrovirus
chemotherapy when NFB activity is also inhibited. Since NFB
mediated expression of the dominant negative p53, p53DDimpinges on multiple aspects of tumor progression, such as the
(Bowman et al., 1996), partially blocks DoxR-mediated cellcontrol of apoptosis, cell cycle, and cell migration, it is critical
death in IKK1/2/ MEFs (Figure 1E). Similarly, p53DD also par-to understand the mechanistic basis of the observation that
tially blocks cell death in WT MEFs (see below; Figure 5B). Weblocking NFB is a useful means of blocking acquired resistance
conclude that DoxR-induced p53 in WT and IKK1/2/ MEFsto chemotherapy.
is: (1) modified upon DNA damage; (2) transactivation compe-In this study, we have used IKK1/2/ MEFs to decipher the
tent; (3) correctly localized in the cell; and (4) capable of inducingrole of IKKs and NFB in regulating the p53 response induced
cell death.by the anticancer agent doxorubicin (DoxR). We find that lack
of IKK2 activity and the consequent inability to activate NFB
Reduction of DoxR-induced cell death and p53facilitates p53 stabilization and promotes cell death. Our results
stabilization by IKK2not only provide evidence of selectivity in NFB activation by
Since the IKK1/2/ MEFs were sensitive to DoxR-induced cellthe IB kinases but also show that IKK2 plays a unique role in
death and accumulation of p53, we tested if reconstitution withactivating NFB and in compromising p53 function in response
IKK1 or IKK2 could reverse p53 accumulation and cell death.to chemotherapy.
IKK1/2/ cells were infected with recombinant adenoviruses
(rAD) expressing IKK1WT (rAD-IKK1WT), the kinase inactiveResults
IKK1KM (rAD-IKK1KM), IKK2WT (rAD-IKK2WT), and kinase in-
active IKK2KM (rAD-IKK2KM). As a control, cells were infectedMEFs lacking IKK1 and IKK2 are more sensitive
with rAD-GFP, a virus expressing the green fluorescent protein.to DoxR-induced cell death and p53 stabilization
Recombinant IKK1 and IKK2 proteins were detected using HAThe role of IKK1 and IKK2 in DoxR sensitivity was evaluated
using spontaneously immortalized MEFs from IKK1/2/ and and flag tags, respectively. Only transduction with rAD-IKK2WT
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Figure 1. DoxR-induced cell death and p53 sta-
bilization in MEFs
A: WT and IKK1/2/ MEFs were plated in six-well
plates and allowed to reach confluence. Cells
were treated with 0.7 g/ml DoxR and percent-
age survival was calculated as described. B:
Confluent cells grown in 6-well dishes were
treated with varying does of DoxR. Whole cell
lysates were prepared in 2 SDS gel loading
buffer and subjected to Western blot analysis
with the indicated antibodies. C: Confluent WT
and IKK1/2/ MEFs were treated with 0.7 g/ml
DoxR and whole cell extracts prepared. Total
and Ser-18 phosphorylated p53 levels were de-
tected using clone PA421 and Phospho-p53 (Ser
15) 16G8 antibody, respectively. D: WT and
IKK1/2/ MEFs were treated with 0.5 g/ml of
DoxR, and whole cell lysates were prepared and
resolved on a 15% gel. Level of p21 induction
was detected using p21 (H-164) antibody. E:
IKK1/2/ MEFs were either mock infected or in-
fected with pLXSN-p53DD retrovirus expressing
p53DD. Pools of infected cells were treated with
DoxR (0.4 g/ml). Forty-eight hours after DoxR
addition, surviving cells were stained. The expres-
sion of p53DD protein was confirmed using PA421
antibody (data not shown).
dramatically reduced the accumulation of p53 in response to molecular distinction between IKK1 and IKK2 in antagonizing
DoxR-induced p53 stabilization, we evaluated the potential ofDoxR in IKK1/2/ cells (Figure 2A, lane 8). Northern blot analysis
(Figure 2B) revealed comparable levels of p53 messenger RNA these kinases to activate NFB in IKK1/2/ cells. Gel shift
analysis demonstrated that IKK2 (Figure 3A, lane 3) but not IKK1in rAD-GFP, rAD-IKK2WT, and rAD-IKK2KM transduced cells,
indicating that IKK2WT-mediated effects on p53 stabilization was able to induce NFB DNA binding in these MEFs. The
binding to the Oct-1 probe was used as a loading control foroperate at the posttranscriptional level. Furthermore, cells ex-
pressing IKK2WT but not IKK1WT or the kinase inactive IKKs the nuclear lysates prepared from IKK1/2/ cells expressing
GFP, IKK1, and IKK2. Treatment of IKK1/ MEFs with DoxRwere also more resistant to DoxR-induced cell death (Figure 2C).
To test the generality of our observations, we determined induced NFB DNA binding (Figure 3B). Since IKK1/ cells
contain IKK2, activation of NFB in response to DoxR in thesewhether IKK2WT could block p53 stabilization in response to
cells supports the notion that this activity is mediated by IKK2.another anticancer agent, etoposide. We found that IKK2WT
reduced p53 stabilization (Figure 2D) and cell death (data not
IKK2 mediated events require activation of NFBshown) in response to etoposide. We conclude that IKK2 sig-
We next tested if IKK2-mediated activation of NFB accountsnificantly antagonizes the ability of anticancer agents like DoxR
for the observed difference in the abilities of IKK1 and IKK2 toor etoposide to increase p53 abundance and subsequent apo-
regulate p53 levels. To address this question, we used cell linesptosis.
expressing IBM, a dominant negative form of IB molecule
that blocks NFB activation (Van Antwerp et al., 1996). TheIKK2 but not IKK1 can activate NFB
NFB pathway is the only signaling cascade documented to be IKK1/2/ MEFs were transduced with retroviral constructs
pLXSH or pLXSH-IBM to generate stable cell lines (IKK1/modulated by IKK1 and IKK2 in vivo. To better understand the
CANCER CELL : JUNE 2002 495
A R T I C L E
Figure 2. Expression of IKK2WT blocks DoxR and
etoposide-induced p53 stabilization and cell
death
A: IKK1/2/ MEFs were cultured in six well dishes.
Freshly confluent cells were infected with re-
combinant adenoviruses (rAD), expressing GFP
(rAD-GFP), IKK1WT (rAD-IKK1WT), IKK1KM (rAD-
IKK1KM), IKK2WT (rAD-IKK2WT), or IKK2KM (rAD-
IKK2KM) in 300l DMEM with 5% FCS and antibiot-
ics. The plates were rocked every 10 min and
the infection was allowed to proceed for 2 hr,
following which cells were replenished with me-
dia without removing the virus. This media was
changed with fresh media after overnight incu-
bation at 37C. Forty-eight hours postinfection,
cells were treated with DoxR at 0.4 g/ml, whole
cell lysates were prepared, and Western blot
analysis with the indicated antibodies was per-
formed. IKK1 and IKK2 proteins were detected
using antibodies against HA and Flag tags, re-
spectively. B: Northern blot analysis of IKK1/2/
cells infected with the indicated rADs. Cells were
treated with various concentrations of DoxR
(shown here is 0.5 g/ml) for 24 hr. A total of
8–10 g of total RNA was analyzed by standard
Northern blot hybridization. The complete murine
p53 cDNA and a 200 bp fragment of actin were
used as probes. C: IKK1/2/ MEFs were cultured
and infected in six-well dishes as before and
treated with 0.7 g/ml DoxR. Cell survival was
estimated between 60 and 72 hr. D: IKK2 can
block etoposide-mediated p53 stabilization.
IKK1/2/ MEFs were infected with rAD-GFP, rAD-
IKK2WT, and rAD-IKK2KM as described before.
Forty-eight hours postinfection, cells were
treated with 100 M etoposide. Total lysates
were prepared 20 hr later by directly lysing the
cells in 2 SDS gel loading buffer. Western blot
analysis was performed for the indicated mole-
cules.
2/ Hygro and IKK1/2/ IBM, Figure 4). Unlike in IKK1/2/ next investigated if blocking the endogenous NFB activation
by dominant negative IBM molecule would lower the thresh-Hygro cells, expression of IKK2WT in IKK1/2/ IBM cells had
significantly reduced effect on both, blocking p53 stabilization old for DoxR-mediated p53 induction. We made stable lines
with WT MEFs expressing either empty pLXSH vector (WT-(Figure 4A compare lane 4 and lane 10) and inducing cell death
(Figure 4B) in response to DoxR. The levels of flag-tagged Hygro) or the IBM repressor (WT-IBM). We observed lower
DoxR threshold and increased stabilization of p53 in WT-IBMIKK2WT expressed in IKK1/2/Hygro and IKK1/2/IBM
cells were comparable. The persistence of IBM (Figure 4A, MEFs (Figure 5A, compare lanes 3 and 4). While expression of
IBM sensitized WT MEFs to cell death induced by DoxR,lanes 7–12) compared to IB (Figure 4A, lanes 1–6) confirms
its inability to be modified and degraded. These results support expression of p53DD could significantly reduce this death (Fig-
ure 5B).the notion that NFB activity is required for blocking DoxR-
induced p53 and cell death.
IKK2 but not IKK1 can upregulate Mdm2
Since the ubiquitin ligase Mdm2 is a key determinant of p53Endogenous levels of NFB inhibit p53 activation
Overexpression of IKK2WT resulted in constitutive levels of nu- stability, we examined whether IKK2-mediated destabilization
of p53 occurred through Mdm2. Reconstitution with IKK2WTclear NFB in both IKK1/2/ and WT MEFs (data not shown).
Although such constitutive NFB activity is seen in various tumor and not IKK1WT upregulated the levels of Mdm2 protein (Figure
6A, lane 4). However, unlike in IKK1/2/ or WT cells, overex-cells and is important in reducing p53 levels in our assays, we
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Figure 4. IKK2-mediated block of p53 stabilization and cell death requires
activation of NFB
A: IKK1/2/ MEFs were infected with either pLXSH or pLXSH-IBM retrovi-Figure 3. NFB DNA binding activity in response to DoxR
ruses and stably selected. Mixed populations of IKK1/2/ Hygro (lane 1–6)A: Gel shift analysis of IKK1/2/ MEFs transduced with the indicated viruses.
and IKK1/2/ IBM cells (lanes 7–12) were infected with rAD-GFP, rAD-
Forty-eight hours postinfection, cells were treated with various concentra-
IKK2WT, and rAD-IKK2KM as described above. Forty-eight hours postinfec-
tions of DoxR (shown here is 0.5 g/ml), and nuclear extracts were prepared
tion, cells were either left untreated or treated with 0.4 g/ml DoxR. p53
and analyzed for NFB DNA binding activity. B: IKK1/ MEFs were treated
levels were measured in whole cell lysates using PA421 antibody. Actin
with indicated doses of DoxR and analyzed for gel shift activity. The oct-1
levels were used to normalize for protein loading. Expression of IKK2 and
probe was used as loading control.
IB proteins was measured using the Flag M2 and IB (C-21) antibodies,
respectively. B: IKK1/2/ Hygro and IKK1/2/ IBM were infected with rAD-
GFP, rAD-IKK2WT, and rAD-IKK2KM as described and treated with 0.7 g/
ml DoxR 48 hr postinfection. Cell survival was estimated as described before.
pression of IKK2WT in p53/ did not lead to upregulation of
Mdm2 (Figure 6B, compare lanes 2 and 5). Transducing
IKK1/2/Hygro cells with increasing MOI of rAD-IKK2WT but not IKK2KM increased the levels of Mdm2 RNA in
caused a concomitant increase in the levels of Mdm2 protein IKK1/2/MEFs (Figure 7C). Unlike in WT and IKK1/2/ MEFs,
(Figure 6C, lanes 2–6), which was blocked by coexpression of overexpression of IKK2WT in p53/ MEFs did not lead to in-
IBM (Figure 6C, lanes 8–12), implicating that NFB activity is crease in Mdm2 RNA (data not shown). These results suggest
essential for IKK2-mediated upregulation of Mdm2. Comparable that IKK2WT-mediated increase of Mdm2 mRNA requires p53
levels of IKK2 were expressed in both cell types (Figure 6C, activity, and that the observed upregulation of Mdm2 protein
lanes 2–6 and 8–12). Notably, levels of p53 at a constant dose by IKK2 most likely results from increased levels of its mRNA.
of DoxR were much lower in IKK1/2/Hygro cells (Figure 6C, To test if Mdm2 is a direct target of NFB, we stimulated
lanes 2–6) than in the corresponding IKK1/2/IBM cells (Fig- WT and IKK1/2/ cells with TNF, a potent activator of NFB.
ure 6C, lanes 8–12), once again indicating increased p53 levels As expected, TNF treatment increased levels of NFB target
in the absence of NFB activity. gene IB in WT but not in IKK1/2/ cells (Figure 7D). However,
we did not observe an increase in Mdm2 RNA in this time scale
Modulation of Mdm2 messenger RNA levels (Figure 7D). Treatment of IKK1/2/ cells with DoxR demon-
Northern blot analysis consistently revealed lower steady-state strated comparable or higher levels of Mdm2 in cells expressing
levels of Mdm2 mRNA in IKK1/2/, p65/ (data not shown), IKK2WT (Figure 7E, compare lanes 2, 4, and 6). We conclude
and p53/ MEFs compared to WT MEFs (Figure 7A). Based that IKK2-mediated NFB activation modulates basal levels of
on densitometric quantification, IKK1/2/ had 40% less Mdm2 Mdm2, and additionally contributes to Mdm2 induction follow-
ing DNA damage.mRNA than WT MEFs (Figure 7B). Reconstitution with IKK2WT
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induction in response to DoxR (Figure 1) and etoposide (Figure
2). Reconstitution of IKK2 but not IKK1 can block this sensitivity
to p53 stabilization (Figure 2). Since IKK2 does not downregulate
the endogenous p53 promoter (Figure 2B) and upregulates
Mdm2 expression (Figure 6A), our results indicate that IKK2
suppresses stabilization of the p53 protein. In addition to a role
in cancer treatment, IKK2-mediated regulation of Mdm2 and
p53 may have important implications in tumor progression. In
tumors with wild-type p53, NFB-induced Mdm2 might attenu-
ate the p53 response in early phases of tumor development.
NFB-induced Mdm2 overexpression could also counter mu-
tant forms of p53 that retain some p53 functions (Friedlander
et al., 1996). Finally, given that p53-independent transformation
properties of Mdm2 have been reported (Cordon-Cardo et al.,
1994), NFB-induced Mdm2 might contribute to tumor progres-
sion in a p53-independent manner.
NFB has been shown to protect against a variety of cellular
insults (Baichwal and Baeuerle, 1997). Antiapoptotic genes in-
cluding scavenger enzyme MnSOD, inhibitors of apoptosis
c-IAP1 and c-IAP2, Bcl-2 homologs such as Bfl1/A1 and Bcl-x,
and the transcription factor A20 have been proposed to mediate
NFB dependent survival signals (Barkett and Gilmore, 1999).
Intuitively, the IKK1/2/ MEFs would fail to activate these NFB
dependent antiapoptotic genes which might be required for
protection against both p53 dependent and independent cell
death. While reconstitution of IKK2 and thus NFB activity in
IKK1/2/ MEFs should reconstitute the function of these anti-
apoptotic genes, the exact contribution of NFB in specifically
repressing p53 dependent cell death in IKK1/2/MEFs remains
Figure 5. Endogenous levels of NFB modulate DoxR-mediated induction of unclear.
p53 and cell death
Genetic analysis of IKK1/ and IKK2/ single knockout
A: WT MEFs were infected with pLXSH or pLXSH-IBM retroviruses to gener- mice clearly points to the distinct roles these kinases play in
ate stable pools WT-Hygro and WT-IBM, respectively. These cells were
vivo (Li et al., 1999a, 1999b). However, given that these kinasesplated in six-well dishes and confluent cells were treated with indicated
are intimately associated in the IKK signalosome, which is cru-doses of DoxR for 18 hr. Cells were washed with PBS and directly lysed in
2 SDS buffer. Western blot analysis with p53 and actin antibodies was cial for NFB activation, individual contributions of IKK1 and
performed as described before. B: WT MEFs were either mock infected or IKK2 in NFB activation have been intensively probed. While
infected with retroviruses encoding IBM and p53DD. Pools of infected
IKK2 is crucial for IB degradation, IKK1 has recently beencells were treated with 0.7 g/ml DoxR and cell survival was estimated as
postulated to be required for a second NFB-activating pathwaydescribed previously.
(Senftleben et al., 2001). In this study we have reconstituted
IKK1 and IKK2 in cells lacking both these kinases. Our results
clearly demonstrate that IKK2 is both necessary and sufficient
to activate NFB (Figure 3) and block p53 stabilization and cellDiscussion
death in a NFB-dependent manner (Figure 4). Genetic analysis
using IKK2/ MEFs had revealed that IKK1 homodimers canCell proliferation reflects the interplay of cell survival and cell
activate NFB DNA binding in response to TNF (Li et al.,death pathways. It is becoming apparent that the effectiveness
1999b). The inability of IKK1 to activate NFB activity in re-of chemotherapeutic agents may similarly reflect their relative
sponse to DoxR in our assay could indicate that unlike IKK2,abilities to paradoxically activate cell death and cell survival
IKK1-mediated NFB activation might occur only in responsepathways. p53 has been demonstrated to be important for mod-
to selective upstream signals. These results reiterate that apartulating cell death in response to chemotherapeutic agents (Lowe
from activating different signaling cascades in vivo, distinct ge-et al., 1993a). However, a correlation between wild-type status
netic roles of these kinases could also be reflective of theirof p53 and response to chemotherapy is not uniformly observed
differential abilities to activate NFB. Designing IKK1 and IKK2in tumors. In part, this is due to alterations in other factors that
specific inhibitors could be instrumental in selectively blockingregulate p53 abundance or function, such as amplification of
NFB in response to distinct upstream signals.Mdm2 (Oliner et al., 1992) and HER-2/neu (Zhou et al., 2001),
Hodgkins lymphoma (Sovak et al., 1997) and breast cancerand mutations/deletions in INK4a/ARF loci (Sherr, 1998). Addi-
(Nakshatri et al., 1997) cell lines have constitutively elevatedtional mutations and genetic variability might be other crucial
modifiers of a tumor’s response to chemotherapy. The findings levels of nuclear NFB. Blocking of NFB activity has been
shown to inhibit ras mediated transformation (Mayo et al., 1997).presented in this paper implicate the NFB signaling cascade
as a potential modulator of p53 in response to chemotherapy. In addition, human T cell leukemia virus type 1 (HTLV-1) (Sun and
Ballard, 1999) and Epstein-Barr virus (EBV) (Cahir McFarland etWe demonstrate that IKK1/2/ cells that are severely defec-
tive in NFB activity are more sensitive to cell death and p53 al., 1999) are some of the viruses that induce the activity of
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Figure 6. Modulation of Mdm2 protein by IKK2
A: MEFs were infected with the indicated adeno-
viruses. Western blot analysis with SMP14 anti-
body was performed 36 hr later to detect Mdm2
protein. The positions of two nonspecific bands
have been indicated by * in all the blots. The
reactivity of Mdm2 bands was cross-confirmed
with another antibody, Ab-2 (Oncogene re-
search products). B: WT and p53/ MEFs were
transduced with the indicated viruses and levels
of Mdm2 proteins were analyzed 36 to 48 hr post-
infection. C: IKK1/2/Hygro (lanes 1–6) and IKK1/
2/IBM (lanes 7–12) cells were selected as de-
scribed in Figure 4. These cells were either unin-
fected (lanes1 and 7) or infected with increasing
titers of rAdIKK2WT (lanes 2–6 and 8–12). Forty-
eight hours postinfection, only the infected cells
were treated with 0.4 g/ml of DoxR. Cell lysates
were prepared 18 hr after addition of DoxR and
analyzed with the indicated antibodies.
NFB during cellular transformation. Cumulatively, consistent p53/ cells. Since the p53 promoter has been documented to
be upregulated by NFB (Wu and Lozano, 1994), we addressedwith the role of their viral homolog v-rel (Gilmore, 1999), the
NFB family members have been implicated in malignant trans- the concern that NFB mediated upregulation of Mdm2 might
simply be due to the fact that NFB upregulates p53, and p53formation of several mammalian cell types. Defective IB activ-
ity and constitutive IKK activity have been mechanistically linked in turn upregulates Mdm2. However, we do not believe that this
is the case since we do not see increased p53 protein levelsto the persistent nuclear NFB seen in many human tumors
(Rayet and Gelinas, 1999). In our study, expression of IKK2 by overexpression of IKK2WT with or without chemotherapy
(Figure 2A, lanes 7 and 8 or Figure 4A, lanes 3 and 4), andalone was sufficient to cause persistently nuclear NFB activity
(data not shown) and significantly reduced cell death and p53 titration of increasing amounts of IKK2WT at a constant dose
of DoxR showed concomitant increase in Mdm2 protein withoutaccumulation (Figure 4). It is tempting to speculate that human
tumor cells with constitutive NFB activity might exhibit a com- increase in p53 (Figure 6C, lanes 1–6). Further, blocking NFB
using IBM under similar experimental conditions showed in-promised p53 response.
To evaluate the role of p53 in NFB dependent increase in creased p53 (Figure 6C, lanes 7–12), suggesting that this in-
crease in p53 might be a consequence of reduced mdm2 levels.Mdm2, we analyzed whether IKK2 could upregulate Mdm2 in
p53/ MEFs (Figure 6B). Using WT MEFs as matched controls, Finally, the demonstration that lack of NFB activity does not
compromise the ability of DoxR to induce p53 (Figure 1B) sug-we showed that IKK2WT overexpression upregulates Mdm2
protein (Figure 6B) and RNA (data not shown) in WT but not in gests that NFB-mediated upregulation of Mdm2 is not merely
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Figure 8. A proposed model for NFB-mediated modulation of p53
In WT cells, anticancer drugs cause DNA damage and activate p53 via
phosphorylation events. These drugs simultaneously activate NFB via IKK2.
NFB or its target gene(s) cooperates with p53 or its target gene(s) to posi-
tively modulate Mdm2 levels. In cells lacking IKK2, NFB is not activated by
DoxR. The lack of this positive modulation results in lower levels of Mdm2Figure 7. Modulation of Mdm2 mRNA by IKK2
and thus greater sensitivity to p53 stabilization.
A: Total RNA from indicated MEFs was prepared and analyzed for levels of
Mdm2. B: Densitometric quantification of Mdm2 mRNA. Relative percent
of Mdm2 levels are shown. C: IKK1/2/ MEFs were transduced with the
indicated viruses, and levels of Mdm2 were analyzed 48 hr postinfection. D:
WT and IKK1/2/ MEFs were treated with 20 ng/ml of TNF for the indicated NFB or its target gene(s) might cooperate with p53 or its target
timepoints. Complete murine IB and Mdm2 cDNAs were used as probes. gene(s) in modulating Mdm2 levels.
E: IKK1/2/ MEFs were transduced with the indicated viruses and treated
Based on transient transfection of IKK2 along with the 1 kbwith 0.4 g/ml of DoxR 48 hr postinfection. 12–16 hr later, total RNA was
extracted and analyzed for Mdm2 expression by Northern blot analysis. intronic mdm2 promoter (Ouchi et al., 1998) (data not shown)
Actin was used as loading control in all experiments. and results presented in Figure 7D, we suggest that Mdm2 might
not be a direct transcriptional target of NFB. Alternatively, the
upregulation of Mdm2 mRNA by NFB might occur by posttran-
scriptional mechanisms. The only such mechanism that has
reflective of its increased transcription due to enhanced p53 been reported (Hsing et al., 2000) has been documented to
protein levels. operate in a p53-independent manner. Given that IKK2-medi-
A model based on results obtained in this study is presented ated upregulation of Mdm2 mRNA requires p53, which is crucial
in Figure 8. We show that treatment with anticancer drugs acti- for Mdm2 transcription, we believe that IKK2-mediated effects
vates p53 (Figure 1) and NFB (Figure 3). Activation of NFB are more likely to operate at transcriptional level. Recently, p63
occurs selectively through IKK2 (Figure 3). NFB cooperates and p73 have been shown to modulate p53-dependent tran-
with p53 and upregulates Mdm2 by increasing its RNA (Figure scription (Flores et al., 2002). Similarly, NFB might be a positive
7) and protein (Figure 6) levels. There are at least two lines modulator of p53-dependent transcription of Mdm2 and might
of evidence that suggest that IKK2 positively modulates the be required to recruit chromatin remodeling complexes in a p53
expression of Mdm2. First, basal levels of Mdm2 RNA are lower dependent manner. The lack of this positive modulation of p53
in IKK1/2/ (Figure 7A) and p65/ (data not shown) cells, and dependent transcription of Mdm2 in IKK1/2/ MEFs might re-
they can be upregulated by reconstitution of IKK2WT but not sult in lower levels of Mdm2 (Figure 7A) and thus greater sensitiv-
IKK2KM (Figure 7C). Second, in response to DoxR, IKK1/2/ ity to p53 stabilization and cell death (Figure 1).
cells expressing IKK2WT have comparable or higher Mdm2 In contrast to our study, p53-mediated apoptosis was re-
(Figure 7E), despite the fact that they have very low levels of ported to require NFB activation (Ryan et al., 2000). In our
p53 protein (Figure 4, compare lanes 2, 4, and 6). It is conceiv- assays, recombinant adenovirus (rAdp53) mediated overex-
pression of p53 activated Mdm2, p21, and Bax in both WT andable that instead of a direct cooperation between these factors,
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by homologous recombination in 293 cells (Miyake et al., 1996). rAD vectorsIKK1/2/ MEFs (V.T. and I.M.V., unpublished data). However,
do not integrate and replicate in the host cells. Thus, to keep the multiplicity oftransduction with rAdp53 did not induce NFB DNA binding in
infection (MOI) constant, only freshly confluent cells were used for infection. Aeither of these MEFs. In addition, analysis of 	-irradiation-
MOI of 200 has been used in all the experiments described.
induced apoptosis of thymocytes, which is p53 dependent
(Lowe et al., 1993b), did not reveal any differences between WT Western blots
and IKK2/ thymocytes (V.T., I.M.V., E. Dejardin, and D. Green, Typically, cells were cultured in six-well dishes, and confluent cells were
treated with DoxR or etoposide for the indicated times, washed with PBS,unpublished observations). These results indicate that activation
and directly harvested in 2 gel loading buffer containing 100 mM Tris-HClof NFB by p53 is a restricted phenomenon and is not essential
(pH 6.8), 200 mM DTT, 4% SDS, 0.2% bromophenol blue, 20% glycerol,for p53-induced cell death. Ryan and colleagues also found
and -mercaptoethanol. Whole cell extracts were prepared by boiling thethat compared to WT MEFs, p65/ MEFs are less sensitive to
cells collected in the previous step and passing the lysates several times
DoxR-induced cell death. We observe high endogenous p53 through a 25G needle. Lysates were resolved on Tris-glycine SDS gels (10%
levels in unchallenged p65/ MEFs (data not shown). This is for p53, actin, p65, IB, IKK1, IKK2, and Mdm2, and 15% for p21). After
consistent with our observation that NFB can reduce p53 lev- electrophoresis, proteins were transferred on PVDV membrane (Immobilon
P, Millipore) by a overnight transfer, blocked in PBS without Mg2
 and Ca2
els. However, it is possible that the p53 in p65/ MEFs was
containing 0.2% tween-20 and 5% nonfat milk, and probed with the indicatedmutated, as this occurs frequently during spontaneous immor-
antibodies in PBS without Mg2
 and Ca2
 containing 0.2% tween-20 andtalization of MEFs (Harvey and Levine, 1991). The existence of
1% milk.
mutated p53 in p65/ MEFs would be consistent with de-
creased sensitivity of these MEFs to DoxR (Ryan et al., 2000). Electrophoretic mobility shift assay
Additionally, this might explain the extremely low levels of Mdm2 Nuclear extracts were prepared as described previously (Li et al., 1999b).
Cells were washed in ice-cold PBS, scraped off the dish, and lysed for 10mRNA observed in these cells (data not shown).
min on ice using ice-cold hypotonic buffer (buffer A: 10 mM HEPES [pHIn summary, our results support the notion that tumors with
7.9], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and 0.5 mM PMSF). Nucleipersistent activation of NFB should be targeted with strategies
were separated from the lysates obtained in the previous step by a briefwherein chemotherapeutic agents could be combined with spe-
centrifugation at 12,000 g. Nuclear extracts were prepared by a high salt
cific inhibitors of IKK2 for more efficient results. Ironically, al- lysis of the nuclei in buffer containing 20 mM HEPES [pH 7.9], 400 mM NaCl,
though inclusion of such NFB inhibitors could augment chemo- 25% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM
therapeutic response against tumors, these strategies might DTT, incubated at 4C for 20 min, supplemented with 5 vol. of storage buffer
(20 mM HEPES [pH 7.9], 100 mM KCl, 20% glycerol, 0.2 mM EDTA, 0.5sensitize normal bystander cells to p53-induced cell death.
mM PMSF, and 0.5 mM DTT), and vortexed for 10 s. Lysed nuclei were
centrifuged for 10 min at 12,000  g, and the resulting supernatants wereExperimental procedures
referred to as nuclear extracts. The DNA binding reaction was performed
at room temperature in a volume of 20 l, which contained the binding bufferCell culture
(25 mM Tris-HCl [pH 7.5], 1.5 mM EDTA, 7.5% glycerol, 75 mM NaCl, 1.5Spontaneously immortalized murine embryo fibroblasts were cultured in
mM DTT, 0.3% NP-40, and 1 mg/ml BSA), 1 g of poly (dI-dC), probe, andDMEM supplemented with 10% FCS (Hyclone), 100 g/ml penicillin, 100
7–10 g of nuclear proteins. After incubation with the radiolabeled probeg/ml streptomycin, and 250 ng/ml of amphotericin B (Gibco). Doxorubicin
for 30 min, the samples were fractionated on a 4% polyacrylamide gelwas purchased from Sigma and dissolved in Milli Q water at a concentration
and visualized by autoradiography. The NFB and Oct-1 probes have beenof 10 mg/ml as stock. Etoposide (Calbiochem) was reconstituted in DMSO
described previously (Li et al., 1999b).and stored at –20C.
Cell survival assaysRetrovirus generation and stable cell selection
Cells typically were plated in six-well dishes. Confluent cells were treatedTwenty micrograms of vector plasmid was transfected with 5 g of an
with DoxR (0.7 g/ml) for 60–72 hr. To estimate the percentage of survival,expression vector for vesicular stomatitis virus G protein and 1 g of a
cells were stained with 0.05% crystal violet (w/v in 20% methanol) for 10GFP expression plasmid into a cell line 293 gp/bsr (N. Somia and I.M.V.,
min. The excess stain was later washed off with water. The stain retainedunpublished data). Supernatants containing the viruses were recovered 48
by surviving cells was leached in methanol and read immediately at 595 nmand 72 hr later, filtered through a 0.45 micron filter, and used to infect MEFs
using a spectrophotometer. The untreated samples in each cell type wereon three to six successive days. Freshly infected cells were stably selected
considered as 100% survival, and percentage cell survival was quantitatedon hygromycin (200 g/ml).
based on survival of untreated samples.
Antibodies
Northern blot analysisThe murine p53 antibody PA421 used to measure total p53 in all the assays
Total RNA was isolated by TRIzol reagent (GibcoBRL) and quantitated byshown was obtained from Calbiochem (clone PA421). The specificity of the
spectrophotometry. For Northern blot analysis, samples were resolved onp53 immunoreactivity of this antibody was cross-confirmed by using the
1% formaldehyde gels and blotted onto Hybond N
membranes (AmershamFL-393 antibody (Santacruz Biotechnology). The Phospho-p53 (Ser 15) 16G8
Pharmacia). Following crosslinking, the membranes were hybridized to theantibody, which recognizes only serine 18 phosphorylated murine p53, was
probes in QuikHyb hybridization solution using the manufacturers instruc-obtained from New England Biolabs. Anti-actin antibody (Sigma) was used
tions (Stratagene).to detect levels of actin, which served as loading controls in all the experi-
ments. The antibodies against IKK1 (M-280), IKK2 (H470), p65 (C-20), IB
(C-21), IB (C-20), Mdm2 (SMP14), and p21 (H-164) were all from Santacruz Acknowledgments
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